Omnicell, Inc. (NASDAQ:OMCL) Given Consensus Rating of “Hold” by Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received an average recommendation of “Hold” from the six research firms that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $52.33.

Several research analysts have recently issued reports on OMCL shares. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. Craig Hallum increased their price objective on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company cut their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Bank of America decreased their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st.

Insiders Place Their Bets

In other news, Director Mark W. Parrish sold 12,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after buying an additional 273 shares in the last quarter. Johnson Financial Group Inc. acquired a new position in Omnicell during the fourth quarter worth $37,000. Van ECK Associates Corp raised its position in Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Omnicell in the fourth quarter valued at $53,000. Finally, First Horizon Advisors Inc. boosted its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Omnicell Stock Performance

NASDAQ:OMCL opened at $39.72 on Monday. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The company has a fifty day simple moving average of $43.09 and a two-hundred day simple moving average of $43.85. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 147.12, a price-to-earnings-growth ratio of 7.62 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, equities analysts anticipate that Omnicell will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.